124.51
price up icon1.21%   1.49
after-market After Hours: 126.37 1.86 +1.49%
loading
Spruce Biosciences Inc stock is traded at $124.51, with a volume of 200.71K. It is up +1.21% in the last 24 hours and up +1,507% over the past month. Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.
See More
Previous Close:
$123.02
Open:
$131.54
24h Volume:
200.71K
Relative Volume:
0.45
Market Cap:
$70.10M
Revenue:
$7.10M
Net Income/Loss:
$-39.43M
P/E Ratio:
-132.46
EPS:
-0.94
Net Cash Flow:
$-46.50M
1W Performance:
-3.88%
1M Performance:
+1,507%
6M Performance:
-86.69%
1Y Performance:
-90.34%
1-Day Range:
Value
$118.10
$131.54
1-Week Range:
Value
$112.95
$144.00
52-Week Range:
Value
$7.26
$543.38

Spruce Biosciences Inc Stock (SPRB) Company Profile

Name
Name
Spruce Biosciences Inc
Name
Phone
(415) 655-4168
Name
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Name
Employee
20
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
SPRB's Discussions on Twitter

Compare SPRB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SPRB
Spruce Biosciences Inc
124.51 69.32M 7.10M -39.43M -46.50M -0.94
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
422.39 107.73B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
654.48 62.04B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
475.91 62.73B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
836.39 51.09B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
165.29 34.67B 398.11M -1.03B -868.57M -5.7032

Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-11-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-11-24 Downgrade Oppenheimer Outperform → Perform
Mar-14-24 Downgrade Guggenheim Buy → Neutral
Mar-14-24 Downgrade H.C. Wainwright Buy → Neutral
Mar-14-24 Downgrade Ladenburg Thalmann Buy → Neutral
Mar-14-24 Downgrade Leerink Partners Outperform → Market Perform
Mar-14-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-21-24 Initiated Guggenheim Buy
Dec-17-21 Initiated Oppenheimer Outperform
Dec-10-21 Initiated The Benchmark Company Speculative Buy
Nov-16-21 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-19-21 Initiated H.C. Wainwright Buy
Apr-26-21 Resumed Credit Suisse Outperform
Nov-03-20 Initiated Cowen Outperform
Nov-03-20 Initiated Credit Suisse Outperform
Nov-03-20 Initiated RBC Capital Mkts Outperform
Nov-03-20 Initiated SVB Leerink Outperform
View All

Spruce Biosciences Inc Stock (SPRB) Latest News

pulisher
10:25 AM

SPRB: JMP Securities Upgrades Spruce Biosciences to Market Outpe - GuruFocus

10:25 AM
pulisher
05:01 AM

Spruce Biosciences stock upgraded by Citizens on promising MPS IIIB therapy - Investing.com Nigeria

05:01 AM
pulisher
Oct 24, 2025

Levi & Korsinsky Reminds Spruce Biosciences Investors of the Ongoing Investigation into Potential Violations of Securities LawsSPRB - ACCESS Newswire

Oct 24, 2025
pulisher
Oct 22, 2025

Spruce Biosciences CFO vests 2,053 RSUs; owns 6,066 shares - Stock Titan

Oct 22, 2025
pulisher
Oct 22, 2025

SPRB insider filing: CEO nets 3,245 shares after RSU vest - Stock Titan

Oct 22, 2025
pulisher
Oct 22, 2025

The science behind the therapy that catapulted a biopharma’s stock 1,400% and counting - healthcare-brew.com

Oct 22, 2025
pulisher
Oct 22, 2025

Leerink Partners Maintains Spruce Biosciences (SPRB) Market Perform Recommendation - Nasdaq

Oct 22, 2025
pulisher
Oct 21, 2025

Spruce Biosciences (SPRB): Analyst Raises Price Target Significa - GuruFocus

Oct 21, 2025
pulisher
Oct 21, 2025

Spruce Biosciences stock price target raised to $160 from $10 at Leerink - Investing.com Philippines

Oct 21, 2025
pulisher
Oct 20, 2025

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025) - ts2.tech

Oct 20, 2025
pulisher
Oct 20, 2025

Mintz Advises the Placement Agents in Spruce Biosciences, Inc.’s $50 Million Private Placement - Mintz

Oct 20, 2025
pulisher
Oct 19, 2025

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough News – Experts Weigh In - ts2.tech

Oct 19, 2025
pulisher
Oct 19, 2025

Spruce Biosciences (NASDAQ:SPRB) Upgraded at Zacks Research - Defense World

Oct 19, 2025
pulisher
Oct 18, 2025

SPRUCE BIOSCIENCES, INC. trading resumes - MSN

Oct 18, 2025
pulisher
Oct 17, 2025

SPRB director steps down; company notes no disagreement - Stock Titan

Oct 17, 2025
pulisher
Oct 17, 2025

Spruce Biosciences, Inc. Announces Resignation of Bali Muralidhar as Member of Board of Directors and as Member of the Compensation Committee of the Board, Effective October 15, 2025 - MarketScreener

Oct 17, 2025
pulisher
Oct 16, 2025

Spruce Biosciences Stock More Than Quadruples After Breakthrough Therapy Designation To Therapy For Rare And Fatal Genetic Disease - MSN

Oct 16, 2025
pulisher
Oct 16, 2025

Head to Head Contrast: PyroGenesis Canada (NASDAQ:PYRGF) vs. Spruce Biosciences (NASDAQ:SPRB) - Defense World

Oct 16, 2025
pulisher
Oct 15, 2025

What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now? - sharewise.com

Oct 15, 2025
pulisher
Oct 15, 2025

Spruce Biosciences’ (SPRB) “Sell (D-)” Rating Reaffirmed at Weiss Ratings - Defense World

Oct 15, 2025
pulisher
Oct 15, 2025

Spruce Biosciences insider filing shows 256-share buy, 1,050 held - Stock Titan

Oct 15, 2025
pulisher
Oct 14, 2025

Spruce Biosciences to sell 502,181 shares at $68.00 in private placement - MSN

Oct 14, 2025
pulisher
Oct 11, 2025

Spruce Biosciences (NASDAQ:SPRB) Shares Down 1% – What’s Next? - Defense World

Oct 11, 2025
pulisher
Oct 11, 2025

Spruce Biosciences (NASDAQ:SPRB) Shares Down 1%What's Next? - MarketBeat

Oct 11, 2025
pulisher
Oct 09, 2025

Medical Stocks To ConsiderOctober 6th - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Promising Pharmaceutical Stocks Worth WatchingOctober 6th - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

$SPRB stock is down 11% today. Here's what we see in our data. - Quiver Quantitative

Oct 09, 2025
pulisher
Oct 08, 2025

Spruce Biosciences, Inc. announced that it has received $49.999769 million in funding - MarketScreener

Oct 08, 2025
pulisher
Oct 08, 2025

Parkman healthcare sells Spruce Biosciences (SPRB) shares for $4920 By Investing.com - Investing.com Canada

Oct 08, 2025
pulisher
Oct 08, 2025

Parkman healthcare sells Spruce Biosciences (SPRB) shares for $4920 - Investing.com India

Oct 08, 2025
pulisher
Oct 08, 2025

SPRUCE BIOSCIENCES, INC. trading halted, volatility trading pause - MSN

Oct 08, 2025
pulisher
Oct 08, 2025

Spruce Biosciences announces $50M private placement financing - TipRanks

Oct 08, 2025
pulisher
Oct 08, 2025

Spruce Biosciences (SPRB) Secures $50M for Therapy Advancements - GuruFocus

Oct 08, 2025
pulisher
Oct 08, 2025

Three Biotech Stocks Jump After Big Regulatory Wins - Finimize

Oct 08, 2025
pulisher
Oct 08, 2025

Spruce Biosciences (SPRB) Secures $50M for Enzyme Replacement Th - GuruFocus

Oct 08, 2025
pulisher
Oct 08, 2025

Spruce Biosciences to Raise $50 Million Through Private Placement; Shares Down Pre-Bell - MarketScreener

Oct 08, 2025
pulisher
Oct 08, 2025

Spruce Biosciences (SPRB) Secures $50 Million for Enzyme Therapy Development - GuruFocus

Oct 08, 2025
pulisher
Oct 08, 2025

Spruce Biosciences secures $50 million in private placement By Investing.com - Investing.com Canada

Oct 08, 2025
pulisher
Oct 08, 2025

Spruce Biosciences secures $50 million in private placement - Investing.com

Oct 08, 2025
pulisher
Oct 08, 2025

Spruce Biosciences (SPRB) Secures $50M in Private Placement for Therapy Advancement - GuruFocus

Oct 08, 2025
pulisher
Oct 08, 2025

Spruce Bio jumps after breakthrough therapy status for enzyme replacement therapy - MSN

Oct 08, 2025
pulisher
Oct 08, 2025

Spruce Biosciences announces $50.0 million private placement financing - MarketScreener

Oct 08, 2025
pulisher
Oct 08, 2025

ContactThe Lethbridge HeraldNews and Sports from around Lethbridge - FinancialContent

Oct 08, 2025
pulisher
Oct 08, 2025

Small Cap Stocks To Follow Today – October 6th - Defense World

Oct 08, 2025
pulisher
Oct 08, 2025

Understanding the Current Trends in SPRB Stock - Info Petite Nation

Oct 08, 2025
pulisher
Oct 08, 2025

Medical Stocks To Consider – October 6th - Defense World

Oct 08, 2025
pulisher
Oct 07, 2025

Biotech And Tech Stocks Rally On Breakthrough News And Partnerships - Finimize

Oct 07, 2025
pulisher
Oct 07, 2025

Spruce Biosciences Stock: Emergent Surges and Market Implications - timothysykes.com

Oct 07, 2025
pulisher
Oct 07, 2025

SPRB Stock Hits 19-Month High Amid Trading Halts - NewsBreak: Local News & Alerts

Oct 07, 2025
pulisher
Oct 07, 2025

Spruce Biosciences’ Breakthrough: Stock Skyrockets - StocksToTrade

Oct 07, 2025

Spruce Biosciences Inc Stock (SPRB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$36.41
price down icon 2.28%
$91.65
price down icon 1.54%
$29.13
price up icon 0.34%
$105.03
price down icon 0.96%
biotechnology ONC
$316.85
price up icon 0.45%
$165.29
price up icon 0.77%
Cap:     |  Volume (24h):